What is Applied Biosensors?
Applied Biosensors specializes in the development of the AMBIS 360, a sophisticated automated buffer and media preparation system tailored for the rigorous demands of cell and gene therapy production. By replacing error-prone manual workflows with precision-engineered automation, the company addresses a critical bottleneck in small-scale biomanufacturing. The platform integrates closed-loop automation and continuous monitoring, providing biomanufacturers with the digital connectivity required for modern, data-driven production environments. This technological shift not only enhances consistency and quality control but also significantly reduces the physical footprint and labor requirements associated with traditional media preparation, positioning Applied Biosensors as a pivotal player in the industrialization of advanced therapies.
How much funding has Applied Biosensors raised?
Applied Biosensors has raised a total of $70K across 1 funding round:
Debt
$70K
Debt (2021): $70K with participation from PPP
Key Investors in Applied Biosensors
PPP
Public-Private Partnership
What's next for Applied Biosensors?
With the recent infusion of capital, Applied Biosensors is poised to transition from its current Series B/C stage into a phase of rapid commercial scaling. The strategic roadmap likely involves expanding the deployment of the AMBIS 360 across global biomanufacturing hubs, where the demand for automated, compliant, and efficient production solutions is at an all-time high. Future growth will likely focus on deepening digital integration capabilities and broadening the system's application range to support larger-scale bioprocessing needs. As the cell and gene therapy market matures, the company's ability to provide reliable, automated infrastructure will be essential for manufacturers aiming to reduce time-to-market while maintaining stringent regulatory standards.
See full Applied Biosensors company page
